SG Americas Securities LLC Purchases 6,330 Shares of Savara Inc (NASDAQ:SVRA)

SG Americas Securities LLC lifted its position in shares of Savara Inc (NASDAQ:SVRA) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,589 shares of the company’s stock after purchasing an additional 6,330 shares during the period. SG Americas Securities LLC’s holdings in Savara were worth $158,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in shares of Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after buying an additional 1,608,522 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after acquiring an additional 1,600,000 shares during the period. Jennison Associates LLC boosted its position in Savara by 17.5% in the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock worth $28,547,000 after purchasing an additional 1,001,296 shares during the last quarter. State Street Corp grew its stake in Savara by 15.7% in the 3rd quarter. State Street Corp now owns 4,138,276 shares of the company’s stock valued at $17,546,000 after purchasing an additional 560,242 shares during the period. Finally, Geode Capital Management LLC grew its stake in Savara by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock valued at $11,564,000 after purchasing an additional 264,825 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $2.77 on Monday. The stock has a market cap of $475.39 million, a price-to-earnings ratio of -6.44 and a beta of 0.63. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 1-year low of $2.59 and a 1-year high of $5.70. The stock’s 50-day moving average is $3.06 and its 200 day moving average is $3.65.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). On average, sell-side analysts anticipate that Savara Inc will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on SVRA shares. Wells Fargo & Company assumed coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target on the stock. Evercore ISI reiterated an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. Finally, HC Wainwright dropped their price objective on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Savara has an average rating of “Moderate Buy” and a consensus target price of $9.86.

Insider Activity at Savara

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was acquired at an average price of $2.95 per share, with a total value of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by company insiders.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.